ProCE Banner Activity

A Banner Year for Myeloma at the 2016 Hematology Meeting

Clinical Thought
Multiple practice-changing myeloma studies were presented at ASH this year. In this commentary, I discuss several key findings clinicians should be aware of.

Released: December 27, 2016

Expiration: December 26, 2017

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Oncology

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees from Kesios, Noxxon, and SkylineDx and funds for research support from AbbVie, Celgene, Janssen, Novartis, sanofi-aventis, and Takeda.